1-Tert-butoxycarbonyl-4-(4-hexyloxyphenyl)-4-hydroxypiperidine | 208537-37-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-Tert-butoxycarbonyl-4-(4-hexyloxyphenyl)-4-hydroxypiperidine
• 英文别名: tert-butyl 4-(4-hexoxyphenyl)-4-hydroxypiperidine-1-carboxylate
• CAS: 208537-37-5
• 化学式: C₂₂H₃₅NO₄
• 分子量: 377.524
• InChiKey: KCEFDNRVVRIVDK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  27
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  59
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-Tert-butoxycarbonyl-4-(4-hexyloxyphenyl)-4-hydroxypiperidine 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 以76%的产率得到4-(4-Hexyloxyphenyl)-1,2,3,6-tetrahydropiridine
  参考文献：
  名称：

  Novel echinocandin antifungals. Part 2: Optimization of the side chain of the natural product FR901379. Discovery of micafungin

  摘要：

  Further optimization of the potent antifungal activity of side chain analogs of the natural product FR901379 led to the discovery of compound 8 with an excellent, well-balanced pro. le. Potent compounds with reduced hemolytic potential were designed based upon a disruption of the linearity of the terphenyl lipophilic side chain. The optimized compound (8, FK463, micafungin) displayed the best balance and was selected as the clinical candidate. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.03.093
• 作为产物：
  描述：

  4-正己氧基溴苯 、 N-叔丁氧羰基-4-哌啶酮 在 magnesium 作用下， 以 乙醚 为溶剂， 以100%的产率得到1-Tert-butoxycarbonyl-4-(4-hexyloxyphenyl)-4-hydroxypiperidine
  参考文献：
  名称：

  Novel echinocandin antifungals. Part 2: Optimization of the side chain of the natural product FR901379. Discovery of micafungin

  摘要：

  Further optimization of the potent antifungal activity of side chain analogs of the natural product FR901379 led to the discovery of compound 8 with an excellent, well-balanced pro. le. Potent compounds with reduced hemolytic potential were designed based upon a disruption of the linearity of the terphenyl lipophilic side chain. The optimized compound (8, FK463, micafungin) displayed the best balance and was selected as the clinical candidate. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.03.093

文献信息

• [EN] CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY<br/>[FR] CYCLOHEXAPEPTIDES AYANT UNE ACTIVITE ANTIMICROBIENNE
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：WO1998023637A1

  公开（公告）日：1998-06-04

  (EN) This invention relates to new polypeptide compounds represented by general formula (I), wherein R1 and R2 are as defined in the description and pharmaceutically acceptable salt thereof which have antimicrobial activities (especially antifungal activities), inhibitory activity on $g(b)-1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for the prophylactic and/or therapeutic treatment of infectious disease including $i(Pneumocystis carinii) infection (e.g. $i(Pneumocystis carinii) pneumonia in a human being or an animal.(FR) Cette invention concerne de nouveaux composés de polypeptides qui correspondent à la formule générale (I) où R1 et R2 sont tels que définis dans la description. Cette invention concerne également les sels de ces composés acceptables sur le plan pharmaceutiques, lesquels possèdent des activités antimicrobiennes et notamment antifongiques, ainsi qu'une activité inhibitrice de $g(b)-1,3-glucan synthase. Cette invention concerne en outre des procédés de préparation de ces composés, ainsi qu'une composition pharmaceutique les contenant. Cette invention concerne enfin un procédé de traitement prophylactique et/ou thérapeutique de maladies infectieuses chez l'homme ou les animaux, y compris d'infections de type $i(Pneumocystis carinii) telles que la pneumonie $i(Pneumocystis carinii).

  该发明涉及一种新的多肽化合物，其通式表示为（I），其中R1和R2如描述中所定义，以及其在药学上可接受的盐，具有抗微生物活性（特别是抗真菌活性），对$g(b)-1,3-葡聚糖合酶的抑制活性，以及制备该化合物的方法，包括制备含有该化合物的制药组合物，以及用于预防和/或治疗包括$ i（Pneumocystis carinii）感染（例如人或动物的$ i（Pneumocystis carinii）肺炎）的传染病的方法。
• CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY
  申请人：——

  公开号：US20020193560A1

  公开（公告）日：2002-12-19

  This invention relates to new polypeptide compounds represented by general formula (I), wherein R 1 and R 2 are as defined in the description and pharmaceutically acceptable salt thereof which have antimicrobial activities (especially antifungal activities), inhibitory activity on &bgr; -1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for the prophylactic and/or therapeutic treatment of infectious disease including Pneumocystis carinii infection (e.g. Pneumocystis carinii pneumonia in a human being or an animal.

  本发明涉及由普通公式（I）表示的新肽类化合物，其中R1和R2如说明书中所定义，以及其药学上可接受的盐，具有抗微生物活性（特别是抗真菌活性），对β-1,3-葡聚糖合酶的抑制活性，制备方法，包括它们的制药组合物，以及用于预防和/或治疗包括卡氏肺孢子虫感染（例如人或动物的卡氏肺孢子虫肺炎）的传染病的方法。
• Cyclohexapeptides having antimicrobial activity
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US06743776B2

  公开（公告）日：2004-06-01

  This invention relates to new polypeptide compounds represented by general formula [I]: wherein R1 and R2 are as defined in the description and pharmaceutically acceptable salt thereof which have antimicrobial activities (especially, antifungal activities), inhibitory activity on &bgr;-1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for the prophylactic and/or therapeutic treatment of infectious disease including Pneumocystis carinii infection (e.g. Pneumocystis carinii pneumonia) in a human being or an animal.

  本发明涉及一种由一般式[I]表示的新型多肽化合物：其中R1和R2如说明书中定义的，并且其药物可接受的盐具有抗微生物活性（特别是抗真菌活性），对β-1,3-葡聚糖合成酶的抑制活性，其制备方法，包含其的制药组合物以及用于预防和/或治疗包括人类或动物的肺孢子菌感染（例如肺孢子菌肺炎）的传染病的方法。
• US6743776B2
  申请人：——

  公开号：US6743776B2

  公开（公告）日：2004-06-01
• Novel echinocandin antifungals. Part 2: Optimization of the side chain of the natural product FR901379. Discovery of micafungin
  作者：Masaki Tomishima、Hidenori Ohki、Akira Yamada、Katsuyuki Maki、Fumiaki Ikeda

  DOI：10.1016/j.bmcl.2008.03.093

  日期：2008.5

  Further optimization of the potent antifungal activity of side chain analogs of the natural product FR901379 led to the discovery of compound 8 with an excellent, well-balanced pro. le. Potent compounds with reduced hemolytic potential were designed based upon a disruption of the linearity of the terphenyl lipophilic side chain. The optimized compound (8, FK463, micafungin) displayed the best balance and was selected as the clinical candidate. (c) 2008 Elsevier Ltd. All rights reserved.